DRUG
Abaloparatide
18 month ABL treatment
Status
Completed
Phase
Phase 4
Enrollment
58
Locations
1
Results
Posted
Publications
12
Study summary
The investigator hypothesizes that treating osteoporotic patients with abaloparatide prior to and after total knee arthroplasty will significantly reduce the amount of bone loss.
In primary unilateral total knee arthroplasty patients, The investigator will examine the effect of daily abaloparatide therapy in clinical osteoporotic patients beginning 3 months pre-op and continued for a total of 15 months. This will be compared to osteopenic patients receiving no therapy as well as previously published values in untreated osteoporotic patients 12 months following Total Knee Arthroplasty (TKA).
Interventions
DRUG
18 month ABL treatment
Timeline
First posted
Nov 18, 2019
Study start
Jan 10, 2020
Primary completion
Apr 3, 2025
Study completion
Apr 3, 2025
Results posted
Jun 5, 2026
Registry updated
Jun 5, 2026
Outcomes
Change in Distal Femoral Bone Mineral Density (BMD) at the 25% Regions of Interest (ROIs)
Time frame · Baseline and approximately 18 months on study (15 months post-TKA)
Bone mineral density change at the 25% ROI of the surgical leg. Dual-energy X-ray absorptiometry (DXA) measured BMD was obtained at a point (ROI) 25% the length of the total surgical femur. Percent change at 25% ROI was calculated from baseline to 18 months.
Change in Distal Femoral BMD at the 15% and 60% ROI
Time frame · Baseline and approximately 18 months on study (15 months post-TKA)
Bone mineral density percent change at the 15% and 60% ROI of the surgical leg
TBS Assessment by TRIP at the 15%, 25%, and 60% Femur ROIs
Time frame · 18 months on study (15 months post-TKA)
Trabecular bone score (TBS) assessment by Texture Research Investigation (Platform (TRIP) software change at the 15% and 25% femur ROIs (TBS \>1.350 is normal; TBS between 1.200 and 1.350 is indicative of partially degraded microarchitecture; and TBS \<1.200 equals degraded microarchitecture).
Knee Injury & Osteoarthritis Outcome Score (KOOS) JR
Time frame · 18 months on study (15 months post-TKA)
Patient reported knee function score. The KOOS, JR was developed from the original long version of the Knee injury and Osteoarthritis Outcome Score (KOOS) survey using Rasch analysis. The KOOS, JR contains 7 items from the original KOOS survey. Items are coded from 0 to 4, none to extreme respectively. KOOS, JR is scored by summing the raw response (range 0-28) and then converting it to an interval score (0-100). The interval score ranges from 0 to 100 where 0 represents total knee disability and 100 represents perfect knee health.
Change in Veterans RAND 12 (VR-12) Question Health Survey Score: Physical Health Component
Time frame · Baseline and approximately 18 months on study (15 months post-TKA)
12 Item Health Survey using patient's self assessment of their perspective of their health and ability to do daily functions. Scores are derived using an algorithm that is referenced to a metric centered at 50.0 where a zero score indicates the lowest level of health and 100 indicates the highest level of health.
Change in Veterans RAND 12 (VR-12) Question Health Survey Score: Mental Health Component
Time frame · Baseline and approximately 18 months on study (15 months post-TKA)
12 Item Health Survey using patient's self assessment of their perspective of their health and ability to do daily functions. Scores are derived using an algorithm that is referenced to a metric centered at 50.0 where a zero score indicates the lowest level of health and 100 indicates the highest level of health.
Forgotten Joint Survey(FJS) Score
Time frame · 18 months on study (15 months post-TKA)
FJS-12 consists of 12 questions and is scored using a 5-point response format with the raw scores transformed onto a 0- to 100-point scale. High scores indicate good outcome, that is, a high degree of forgetting the joint in everyday life (forgotten joint phenomenon).
Change in Body Composition Using Bioelectrical Impedance Analysis of Lean Mass
Time frame · Baseline and approximately 18 months on study (15 months post-TKA)
Change in total body composition using bioelectrical impedance analysis of lean mass.
Change in Body Composition Using Bioelectrical Impedance Analysis of Fat Mass.
Time frame · Baseline and approximately 18 months on study (15 months post-TKA)
Change in total body composition using bioelectrical impedance analysis of fat mass.
TKA Complications: Number of Participants Needed Revision Surgery
Time frame · 18 months on study (15 months post-TKA)
TKA complications: Number of participants needed revision surgery
TKA Complications: Number of Participants Had Fracture
Time frame · 18 months on study (15 months post-TKA)
TKA complications: Number of participants had fracture
Eligibility
Inclusion Criteria 1. Post-menopausal women and men age ge ≥ 55 years and scheduled to undergo primary TKA at the University of Wisconsin Total Joint Program. 2. Osteoporosis, i.e., BMD T-score (using female reference data) ≤ -2.5 at the lumbar spine, femoral neck OR total hip or ≤ -1.1 with Vertebral Fracture Assessment confirmed vertebral fracture or history of low-trauma nonvertebral fracture in the past 5 years OR osteopenia, BMD T-score (using female reference data) -1.1 to -2.4 at the lumbar spine, femoral neck or total hip and no prior low-trauma fracture. 3. Serum calcium (albumin-corrected), serum creatinine and Parathyroid(PTH) values all within the normal range and 25(OH)D \> 10 ng/mL. 4. Willing to supplement with daily calcium and/or vitamin D3 at protocol specified doses. 5. Able to provide written informed consent. Exclusion Criteria 1. Unevaluable distal femur BMD due to hardware or other artifacts. 2. History of bone disorders (e.g., Paget's disease) other than osteoporosis. 3. History of prior external beam or implant radiation therapy involving the skeleton other than radioiodine. 4. History of chronic or recurrent renal, hepatic, pulmonary, allergic, cardiovascular, gastrointestinal, endocrine, central nervous system, hematologic or metabolic diseases, or immunologic, emotional and/or psychiatric disturbances that, in opinion of the principal investigator, would compromise study data validity. 5. History of Cushing's disease, growth hormone deficiency or excess, hyperthyroidism, hypo- or hyperparathyroidism or malabsorptive syndromes within the past year. 6. History of significantly impaired renal function (serum creatinine \>2.0 mg/dL. If the serum creatinine is \> 1.5 and ≤ 2.0 mg/dL, the calculated creatinine clearance (Cockcroft-Gault) must be ≥ 37 mL/min. 7. History of nephrolithiasis or urolithiasis within the past five years. 8. History of cancer in prior 5 years (basal cell or squamous skin cancer is permissible). 9. History of osteosarcoma at any time. 10. Patients known to be positive for Hepatitis B, Hepatitis C, HIV-1 or HIV-2. 11. Known hypersensitivity to any of the test materials or related compounds. 12. Prior treatment with PTH- or PTHrP-derived drugs, (ABL, teriparatide or PTH (1-84)). 13. Prior treatment with intravenous bisphosphonates at any time or oral bisphosphonates within the past three years. Patients who had received a short course of oral bisphosphonate therapy (3 months or less) may be enrolled as long as the treatment occurred 6 or more months prior to enrollment. 14. Treatment with fluoride or strontium in the past five years or prior treatment with bone-acting investigational agents at any time. 15. Treatment with calcitonin the past 6 months or denosumab in the past 18 months. 16. Treatment with anticonvulsants affecting vitamin D metabolism (phenobarbital, phenytoin, carbamazepine or primidone) or chronic heparin within the prior 6 months. 17. Treatment with anabolic steroids or calcineurin inhibitors (cyclosporin, tacrolimus) 18. Daily treatment with oral, intranasal or inhaled glucocorticoids in the prior 12 months. 19. Exposure to any investigational drug within 12 months. 20. Consumption of \> 2 alcoholic drinks per day or use of illegal drugs within 12 months of screening. 21. Not suitable for study participation due to other reasons at the investigators discretion.
Study locations
United States. Showing up to 24 locations stored in the fast local snapshot.
University of Wisconsin
Madison, Wisconsin, United States
Publications
Related trials
State University of New York at Buffalo · Lumbar Degenerative Disease
Phase 2
Enrolling by invitation
60
2026-07
424 General Military Hospital · Osteoporosis, Postmenopausal
Not applicable
Recruiting
150
2026-07
Hospital for Special Surgery, New York · Osteoporosis, Postmenopausal
Phase 4
Active, not recruiting
70
2026-06
Istituto Auxologico Italiano · Osteoporosis · Menopause
Not applicable
Recruiting
42
2026-06
Hospital for Special Surgery, New York · Spinal Fusion
Phase 2
Active, not recruiting
96
2026-04
Qilu Pharmaceutical Co., Ltd. · Postmenopausal Women With Osteoporosis
Phase 3
Not yet recruiting
282
2025-03
The Affiliated Hospital of Qingdao University · Osteoporosis
Phase 1
Not yet recruiting
32
2024-12
David Lunardini · Odontoid Fracture
Phase 2
Terminated
22
2024-09
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.